Evidence map›Paper›PMID 34101213›Full record

ArticleThe EMBO journal2021

SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation.

Lucy G Thorne, Ann-Kathrin Reuschl, Lorena Zuliani-Alvarez, Matthew V X Whelan, Jane Turner, Mahdad Noursadeghi, Clare Jolly, Greg J Towers

Open access · hybridAbstract read
In one paragraph

Article in The EMBO journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 1 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 1 synthesis or guideline pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Defective RNA Polymerase III sensing of mitochondrial DNA in pulmonary epithelial cells impairs type I IFN immunity to SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  14. Article
  15. ACS medicinal chemistry letters · 2026
    Article
  16. Review
  17. Article
  18. Frontiers in immunology · 2026
    Article
  19. Article
  20. Article

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lucy G ThorneDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0001-7358-6047
Ann-Kathrin ReuschlDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0002-1459-3519
Lorena Zuliani-AlvarezDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0002-4682-4043
Matthew V X WhelanDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0003-0441-3358
Jane TurnerDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0001-9358-6001
Mahdad NoursadeghiDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0002-4774-0853
Clare JollyDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0002-4603-2281
Greg J TowersDivision of Infection and Immunity, University College London, London, UK.ORCID 0000-0002-7707-0264
University College London · GB

Funding

Medical Research Council G0801172Medical Research Council MR/S023380/1Medical Research Council MR/W005611/1Wellcome Trust 108079Wellcome Trust 108183Wellcome Trust 207511Wellcome Trust 220863
6 · The paper itself

Abstract

SARS-CoV-2 infection causes broad-spectrum immunopathological disease, exacerbated by inflammatory co-morbidities. A better understanding of mechanisms underpinning virus-associated inflammation is required to develop effective therapeutics. Here, we discover that SARS-CoV-2 replicates rapidly in lung epithelial cells despite triggering a robust innate immune response through the activation of cytoplasmic RNA sensors RIG-I and MDA5. The inflammatory mediators produced during epithelial cell infection can stimulate primary human macrophages to enhance cytokine production and drive cellular activation. Critically, this can be limited by abrogating RNA sensing or by inhibiting downstream signalling pathways. SARS-CoV-2 further exacerbates the local inflammatory environment when macrophages or epithelial cells are primed with exogenous inflammatory stimuli. We propose that RNA sensing of SARS-CoV-2 in lung epithelium is a key driver of inflammation, the extent of which is influenced by the inflammatory state of the local environment, and that specific inhibition of innate immune pathways may beneficially mitigate inflammation-associated COVID-19.

Indexed as

SARS-CoV-2Cell LineCOVID-19CytokinesDEAD Box Protein 58Epithelial CellsHost-Pathogen InteractionsHumansImmunity, InnateInflammationInterferon-Induced Helicase, IFIH1Janus KinasesLungMacrophage ActivationMacrophagesNF-kappa BCytokinesDEAD Box Protein 58IFIH1 protein, humanInterferon-Induced Helicase, IFIH1Janus KinasesNF-kappa BReceptors, ImmunologicRIGI protein, humanRNA, ViralSTAT Transcription FactorsepithelialinflammationmacrophageRNA sensingSARS-CoV-2

Identifiers

PMID34101213
PMCPMC8209947
OpenAlexW3167578500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.